CEBPB and cancer: C/EBPα is inactivated in multiple tumor types [12], whereas the naturally occurring dominant negatively acting C/EBPβ/LIP is upregulated in breast cancer [14], suggesting that unbalanced expression of C/EBPβ isoforms may contribute to cancer progression.